Design of population pharmacokinetic experiments using prior information

References

• Aarons L. Population pharmacokinetics: Theory and practice. British Journal of Clinical Pharmacology 1991; 32: 669–670
   PubMed Web of Science ®Google Scholar
• Aarons L. Population pharmacokinetics. International Journal of Clinical Pharmacology. Therapeutics and Toxicology 1992; 30: 520–522
   Google Scholar
• Aarons L. Software for population pharmacokinetics and pharmacodynamics. Clinical Pharmacokinetics 1999; 36: 255–264
   PubMed Web of Science ®Google Scholar
• Aarons L, Balant LP, Mentré F, Morselli PL, Rowland M, Steimer JL, Vozeh S. Practical experience and issues in designing and performing population pharmacokinetic/pharmacodynamic studies. European Journal of Clinical Pharmacology 1996; 49: 251–254
   PubMed Web of Science ®Google Scholar
• Al Banna MK, Kelman AW, Whiting B. Experimental design and efficient parameter estimation in population pharmacokinetics. Journal of Pharmacokinetics and Biopharmaceutics 1990; 18: 347–360
   PubMedGoogle Scholar
• Atkinson AC, Chaloner K, Herzberg AM, Juritz J. Optimum experimental designs for properties of a compartmental model. Biometrics 1993; 49: 325–337
   PubMed Web of Science ®Google Scholar
• Atkinson AC, Donev AN. Optimum experimental designs. Oxford University Press, Oxford 1992
   Google Scholar
• Atkinson AC, Haines LM. Designs for nonlinear and generalized linear models. Handbook of statistics 13, S Ghosh, CR Rao. Elsevier Science, Amsterdam 1996; 437–476
   Google Scholar
• Bogacka B, Patan M. Efficient sampling windows for parameter estimation in population models. Population Approach Group Europe (PAGE). 15: Abstr 963. 2006
   Google Scholar
• Chaloner K, Larntz K. Optimal Bayesian design applied to logistic regression experiments. Journal of Statistical Planning and Inference 1989; 21: 191–208
   Web of Science ®Google Scholar
• Chenel M, Ogungbenro K, Duval V, Laveille C, Jochemsen R, Aarons L. Optimal blood sampling time windows for parameter estimation using a population approach: Design of a phase II clinical trial. Journal of Pharmacokinetics and Pharmacodynamics 2005; 32: 737–756
   PubMed Web of Science ®Google Scholar
• Colburn WA, Lee JW. Biomarkers, validation and pharmacokinetic–pharmacodynamic modelling. Clinical Pharmacokinetics 2003; 42: 997–1022
   PubMed Web of Science ®Google Scholar
• Cooper L, Steinberg D. Introduction to methods of optimisation. W. B. Saunders, Philadelphia, PA 1970
   Google Scholar
• Corana A, Marchesi M, Martini C, Ridella S. Minimizing multimodal functions of continuous variables with the ‘simulated annealing’ algorithm. ACM Transactions on Mathematical Software 1987; 13: 262–280
   Web of Science ®Google Scholar
• d’Argenio DZ. Optimal sampling times for pharmacokinetic experiments. Journal of Pharmacokinetics and Biopharmaceutics 1981; 9: 739–756
   PubMedGoogle Scholar
• d’Argenio DZ. Incorporating prior parameter uncertainty in the design of sampling schedules for pharmacokinetic parameter estimation experiments. Mathematical Biosciences 1990; 99: 105–118
   PubMed Web of Science ®Google Scholar
• Dufull S, Ecdeston JA, Kimko HC, Denman N. WinPOPT: Optimization for population PKPD study design. 2006, http://www.winpopt.com
   Google Scholar
• Duffull SB, Mentré F, Aarons L. Optimal design of a population pharmacodynamic experiment for ivabradine. Pharmaceutical Research 2001; 18: 83–89
   PubMedGoogle Scholar
• Duffull SB, Retout S, Mentré F. The use of simulated annealing for finding optimal population designs. Computer Methods and Programs in Biomedicine 2002; 69: 25–35
   PubMed Web of Science ®Google Scholar
• Endrenyi L. Design of experiments for estimating enzyme and pharmacokinetic parameters in kinetic data analysis. Design and analysis of enzyme and pharmacokinetic experiments, L Endrenyi. Plenum, New York, NY 1981; 121–167
   Google Scholar
• Endrenyi L, Chan FY. Optimal design of experiments for the estimation of precise hyperbolic kinetic and binding parameters. Journal of Theoretical Biology 1981; 90: 241–263
   PubMed Web of Science ®Google Scholar
• Fedorov VV. Theory of experiments. Academic Press, New York, NY 1972
   Google Scholar
• Fedorov VV, Hackl P. Model-oriented design of experiments. Springer, New York, NY 1997
   Google Scholar
• Foracchia M, Hooker A, Vicini P, Ruggeri A. POPED, a software for optimal experiment design in population kinetics. Computer Methods and Programs in Biomedicine 2004; 74: 29–46
   PubMed Web of Science ®Google Scholar
• Gagnon R, Leonov S. Optimal population designs for PK models with serial sampling. Journal of Biopharmaceutical Statistics 2005; 15: 143–163
   PubMed Web of Science ®Google Scholar
• Goffe WL, Ferrier GD, Rogers J. Global optimization of statistical functions with simulated annealing. Journal of Econometrics 1994; 60: 65–99
   Web of Science ®Google Scholar
• Graham G, Aarons J. Optimal blood sampling time windows for parameter estimation in individual and population pharmacokinetic experiments. Statistics in Medicine 2004; 25: 4004–4019
   Google Scholar
• Green B, Duffull SB. Development of a dosing strategy for enoxaparin in obese patients. British Journal of Clinical Pharmacology 2003a; 56: 96–103
   PubMed Web of Science ®Google Scholar
• Green B, Duffull SB. Prospective evaluation of a D-optimal designed population pharmacokinetic study. Journal of Pharmacokinetics and Pharmacodynamics 2003b; 30: 145–161
   PubMed Web of Science ®Google Scholar
• Gueorguieva I, Aarons L, Ogungbenro K, Jorga KM, Rodgers T, Rowland M. Optimal design for multivariate response pharmacokinetic models. Journal of Pharmacokinetics and Pharmacodynamics 2006; 33: 97–124
   PubMed Web of Science ®Google Scholar
• Gueorguieva I, Ogungbenro K, Graham G, Glatt S, Aarons L. A program for individual and population optimal design for univariate and multivariate response pharmacokinetic–pharmacodynamic models. Computer Methods and Programs in Biomedicine 2007; 86: 51–61
   PubMed Web of Science ®Google Scholar
• Haines LM. The application of the annealing algorithm to the construction of exact optimal designs for linear-regression models. Technometrics 1987; 29: 439–447
   Web of Science ®Google Scholar
• Hale M, Gillespie WR, Gupta SK, Tuk B, Holford NH. Clinical trial simulation, streamlining your drug development process. Applied Clinical Trials 1996; 5: 35–40
   Google Scholar
• Hashimoto Y, Sheiner LB. Designs for population pharmacodynamics: Value of pharmacokinetic data and population analysis. Journal of Pharmacokinetics and Biopharmaceutics 1991; 19: 333–353
   PubMedGoogle Scholar
• Hennig S, Waterhouse TH, Bell SC, France M, Wainwright CE, Miller H, Charles BG, Duffull SB. A d-optimal designed population pharmacokinetic study of oral itraconazole in adult cystic fibrosis patients. British Journal of Clinical Pharmacology 2007; 63: 438–450
   PubMed Web of Science ®Google Scholar
• Holford NH, Sheiner LB. Kinetics of pharmacologic response. Pharmacology and Therapeutics 1982; 16: 143–166
   PubMed Web of Science ®Google Scholar
• Jonsson EN, Wade JR, Karlsson MO. Comparison of some practical sampling strategies for population pharmacokinetic studies. Journal of Pharmacokinetics and Biopharmaceutics 1996; 24: 245–263
   PubMedGoogle Scholar
• Kang D, Schwartz JB, Verotta D. A sample size computation method for non-linear mixed effects models with applications to pharmacokinetic models. Statistics in Medicine 2004; 23: 2551–2566
   PubMed Web of Science ®Google Scholar
• Kang D, Schwartz JB, Verotta D. Sample size computations for PK/PD population models. Journal of Pharmacokinetics and Pharmacodynamics 2005; 32: 685–701
   PubMedGoogle Scholar
• Kowalski KG, Hutmacher MM. Design evaluation for a population pharmacokinetic study using clinical trial simulations: A case study. Statistics in Medicine 2001; 20: 75–91
   PubMed Web of Science ®Google Scholar
• Lagarias JC, Reeds JA, Wright MH, Wright PE. Convergence of the Nelder–Mead simplex method in low dimensions. SIAM Journal of Optimisation 1998; 9: 112–147
   Web of Science ®Google Scholar
• Lee PI. Design and power of a population pharmacokinetic study. Pharmaceutical Research 2001; 18: 75–82
   PubMedGoogle Scholar
• Masri SF, Bekey GA. A global optimisation algorithm using adaptive random search. Applied Mathematics and Computing 1980; 7: 353–375
   Web of Science ®Google Scholar
• McKinnon KIM. Convergence of the Nelder–Mead simplex method to a nonstationary point. SIAM Journal of Optimisation 1998; 9: 148–158
   Web of Science ®Google Scholar
• Mentré F, Mallet A, Baccar D. Optimal design in random-effects regression models. Biometrika 1997; 84: 429–442
   Web of Science ®Google Scholar
• Merle Y, Mentré F. Bayesian design criteria: Computation, comparison, and application to a pharmacokinetic and a pharmacodynamic model. Journal of Pharmacokinetics and Biopharmaceutics 1995; 23: 101–125
   PubMedGoogle Scholar
• Montgomery DC. Design and analysis of experiments5th. Wiley, New York, NY 2001
   Google Scholar
• Nelder JA, Mead R. A simplex method for function minimization. Computer Journal 1965; 7: 308–313
   Web of Science ®Google Scholar
• Ogungbenro K, Aarons L. Sample size calculation based on confidence interval for pharmacokinetic experiments. Population Approach Group Europe (PAGE). 12: Abstr 404. 2003
   Google Scholar
• Ogungbenro K, Aarons L, Graham G. Sample size calculations based on generalized estimating equations for population pharmacokinetic experiments. Journal of Biopharmaceutical Statistics 2006; 16: 135–150
   PubMed Web of Science ®Google Scholar
• Ogungbenro K, Graham G, Gueorguieva I, Aarons L. The use of a modified Fedorov exchange algorithm to optimise sampling times for population pharmacokinetic experiments. Computer Methods and Programs in Biomedicine 2005; 80: 115–125
   PubMed Web of Science ®Google Scholar
• Ogungbenro K, Gueorguieva I, Majid O, Graham G, Aarons L. Optimal design for multiresponse pharmacokinetic–pharmacodynamic models: Dealing with unbalanced designs. Journal of Pharmacokinetics and Pharmacodynamics Accepted 05-07-2007. 2007
   Google Scholar
• Press WH, Flannery BP, Teukolsky SA, Vettering WT. Numerical recipes in C. Cambridge University Press, Cambridge 1988
   Google Scholar
• Pronzato L. Information matrices with random regressors. Application to experimental designs. Journal of Statistical Planning and Inference 2002; 108: 189–200
   Google Scholar
• Pronzato L, Walter E. Robust experiment design via stochastic approximation. Mathematical Biosciences 1985; 75: 103–120
   Web of Science ®Google Scholar
• Pronzato L, Walter E, Venot A, Lebruchec JF. A general-purpose global optimizer: Implementation and applications. Mathematics and Computers in Simulation 1984; 26: 412–422
   Web of Science ®Google Scholar
• PWC. PriceWaterhouseCoopers Pharma 2005. 2005, an industrial revolution in R&D (available at: http://www.pwc.com/gx/eng/about/ind/pharma/industrial_revolution.pdf)
   Google Scholar
• Retout S, Comets E, Nagard HL, Mentré F. New features for population design evaluation and optimisation in R:PFIM 2.0 and PFIMOPT 2.0. Population Approach Group Europe (PAGE). 2006; 15, Abstr 1006
   Google Scholar
• Retout S, Duffull S, Mentré F. Development and implementation of the population Fisher information matrix for the evaluation of population pharmacokinetic designs. Computer Methods and Programs in Biomedicine 2001; 65: 141–151
   PubMed Web of Science ®Google Scholar
• Retout S, Mentré F. Further developments of the Fisher information matrix in nonlinear mixed effects models with evaluation in population pharmacokinetics. Journal of Biopharmaceutical Statistics 2003a; 13: 209–227
   PubMedGoogle Scholar
• Retout S, Mentré F. Optimization of individual and population designs using Splus. Journal of Pharmacokinetics and Pharmacodynamics 2003b; 30: 417–443
   PubMed Web of Science ®Google Scholar
• Retout S, Mentré F, Bruno R. Fisher information matrix for non-linear mixed-effects models: Evaluation and application for optimal design of enoxaparin population pharmacokinetics. Statistics in Medicine 2002; 21: 2623–2639
   PubMed Web of Science ®Google Scholar
• Ribbing J, Jonsson EN. Power, selection bias and predictive performance of the population pharmacokinetic covariate model. Journal of Pharmacokinetics and Pharmacodynamics 2004; 31: 109–134
   PubMed Web of Science ®Google Scholar
• Rowland M, Tozer T. Clinical pharmacokinetics, concepts and applications4th. Lippincott Williams & Wilkins, Philadelphia, PA 2005
   Google Scholar
• Sheiner LB, Rosenberg B, Marathe VV. Estimation of population characteristics of pharmacokinetic parameters from routine clinical data. Journal of Pharmacokinetics and Biopharmaceutics 1977; 5: 445–479
   PubMedGoogle Scholar
• Tod M, Mentré F, Merle Y, Mallet A. Robust optimal design for the estimation of hyperparameters in population pharmacokinetics. Journal of Pharmacokinetics and Biopharmaceutics 1998; 26: 689–716
   PubMedGoogle Scholar
• Tod M, Rocchisani JM. Implementation of OSPOP, an algorithm for the estimation of optimal sampling times in pharmacokinetics by the ED, EID and API criteria. Computer Methods and Programs in Biomedicine 1996; 50: 13–22
   PubMed Web of Science ®Google Scholar
• Tod M, Rocchisani JM. Comparison of ED, EID, and API criteria for the robust optimization of sampling times in pharmacokinetics. Journal of Pharmacokinetics and Biopharmaceutics 1997; 25: 515–537
   PubMedGoogle Scholar
• Vozeh S, Steimer JL, Rowland M, Morselli P, Mentré F, Balant LP, Aarons L. The use of population pharmacokinetics in drug development. Clinical Pharmacokinetics 1996; 30: 81–93
   PubMed Web of Science ®Google Scholar
• Walter E, Pronzato L. Optimal experiment design for nonlinear models subject to large prior uncertainties. American Journal of Physiology 1987; 253: R530–R534
   PubMed Web of Science ®Google Scholar
• Walter E, Pronzato L. Identification of parametric models from experimental data. Springer, London 1997
   Google Scholar
• Wang J, Endrenyi L. A computationally efficient approach for the design of population pharmacokinetic studies. Journal of Pharmacokinetics and Biopharmaceutics 1992; 20: 279–294
   PubMedGoogle Scholar
• Waterhouse TH, Redmann S, Duffull SB, Eccleston JA. Optimal design for model discrimination and parameter estimation for itraconazole population pharmacokinetics in cystic fibrosis patients. Journal of Pharmacokinetics and Pharmacodynamics 2005; 32: 521–545
   PubMed Web of Science ®Google Scholar
• White DB, Walawander CA, Liu DY, Grasela TH. Evaluation of hypothesis testing for comparing two populations using NONMEM analysis. Journal of Pharmacokinetics and Biopharmaceutics 1992; 20: 295–313
   PubMedGoogle Scholar
• WinPOPT: Optimization for population PKPD study design. 2006
   Google Scholar
• Wynn PH. The sequential generation of D-optimum experimental designs. Annals of Mathematical Statistics 1970; 41: 1655–1664
   Google Scholar
• Yuh L, Beal S, Davidian M, Harrison F, Hester A, Kowalski K, Vonesh E, Wolfinger R. Population pharmacokinetic/pharmacodynamic methodology and applications: A bibliography. Biometrics 1994; 50: 566–575
   PubMed Web of Science ®Google Scholar